Alpha 2.0
Login Register
» Authors » Araba A Adjei

Araba A Adjei

Explore the profile of Araba A Adjei including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 21
Citations 545
Followers 0
Related Specialties
Oncology
Pulmonary Medicine
Biochemistry
Top 10 Co-Authors
Richard M Weinshilboum
Alex A Adjei
Grace K Dy
Oreste E Salavaggione
Julian R Molina
Steven E Schild
Janet E Olson
Charles L Loprinzi
Eric D Wieben
Daniel J Schaid
Published In
J Thorac Oncol
J Clin Oncol
Cancer Res
Cancers (Basel)
Biochem Biophys Res Commun
Affiliations
Soon will be listed here.
Recent Articles
1.
Genetic Predictors of Chemotherapy-Induced Peripheral Neuropathy from Paclitaxel, Carboplatin and Oxaliplatin: NCCTG/Alliance N08C1, N08CA and N08CB Study
Adjei A, Lopez C, Schaid D, Sloan J, Le-Rademacher J, Loprinzi C, et al.
Cancers (Basel) . 2021 Apr; 13(5). PMID: 33802509
Chemotherapy-induced peripheral neuropathy (CIPN) is a common and potentially permanent adverse effect of chemotherapeutic agents including taxanes such as paclitaxel and platinum-based compounds such as oxaliplatin and carboplatin. Previous studies...
2.
Genetic Variations and Health-Related Quality of Life (HRQOL): A Genome-Wide Study Approach
Adjei A, Lopez C, Schaid D, Sloan J, Le-Rademacher J, Loprinzi C, et al.
Cancers (Basel) . 2021 Feb; 13(4). PMID: 33578652
Health-related quality of life (HRQOL) is an important prognostic patient-reported outcome in oncology. Because prior studies suggest that HRQOL is, in part, heritable, we performed a GWAS to elucidate genetic...
3.
A randomized, double-blind, placebo-controlled trial of testosterone for treatment of postmenopausal women with aromatase inhibitor-induced arthralgias: Alliance study A221102
Cathcart-Rake E, Novotny P, Leon-Ferre R, Le-Rademacher J, Storrick E, Adjei A, et al.
Support Care Cancer . 2020 May; 29(1):387-396. PMID: 32372176
Purpose: To evaluate the efficacy of testosterone supplementation for improving aromatase inhibitor musculoskeletal symptoms (AIMSS). Methods: Postmenopausal women experiencing moderate-to-severe arthralgias while taking adjuvant aromatase inhibitors for breast cancer were...
4.
NCCTG N0821 (Alliance): a phase II first-line study of pemetrexed, carboplatin, and bevacizumab in elderly patients with advanced nonsquamous non-small-cell lung cancer with good performance status
Dy G, Molina J, Qi Y, Ansari R, Thomas S, Ross H, et al.
J Thorac Oncol . 2014 Aug; 9(8):1146-53. PMID: 25157767
Background: We hypothesized that the combination of bevacizumab, carboplatin, and pemetrexed will be an effective first-line regimen in fit, elderly patients with nonsquamous non-small-cell lung cancer. Methods: Treatment-naïve, stage IIIB/IV...
5.
Phase II study of perioperative chemotherapy with cisplatin and pemetrexed in non-small-cell lung cancer
Dy G, Bogner P, Tan W, Demmy T, Farooq A, Chen H, et al.
J Thorac Oncol . 2014 Jan; 9(2):222-30. PMID: 24419420
Introduction: Pathologic complete response (pCR) with neoadjuvant chemotherapy is associated with improved survival in many solid tumors. We evaluated pCR rate of cisplatin with pemetrexed in non-small-cell lung cancer. Methods:...
6.
Low 25(OH) vitamin D3 levels are associated with adverse outcome in newly diagnosed, intensively treated adult acute myeloid leukemia
Lee H, Muindi J, Tan W, Hu Q, Wang D, Liu S, et al.
Cancer . 2013 Oct; 120(4):521-9. PMID: 24166051
Background: Several studies have suggested that low 25(OH) vitamin D3 levels may be prognostic in some malignancies, but no studies have evaluated their impact on treatment outcome in patients with...
7.
Serum vitamin D metabolites in colorectal cancer patients receiving cholecalciferol supplementation: correlation with polymorphisms in the vitamin D genes
Muindi J, Adjei A, Wu Z, Olson I, Huang H, Groman A, et al.
Horm Cancer . 2013 Mar; 4(4):242-50. PMID: 23456391
Cholecalciferol (D(3)) supplementation results in variable increases in serum 25(OH)D(3) levels, however, the influence of genetic polymorphisms on these variable responses is unclear. We measured serum 25(OH)D(3), 24,25(OH)(2)D(3), 1,25(OH)2D(3) and...
8.
A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528
Dy G, Mandrekar S, Nelson G, Meyers J, Adjei A, Ross H, et al.
J Thorac Oncol . 2012 Dec; 8(1):79-88. PMID: 23232491
Introduction: The purpose of this study was to assess the safety and efficacy of gemcitabine and carboplatin with (arm A) or without (arm B) daily oral cediranib as first-line therapy...
9.
Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study
Adjei A, Salavaggione O, Mandrekar S, Dy G, Allen Ziegler K, Endo C, et al.
J Thorac Oncol . 2010 Jul; 5(9):1346-53. PMID: 20651609
Purpose: To correlate polymorphisms in genes involved in the transport, activation, and inactivation of pemetrexed with the outcome of patients with advanced non-small cell lung cancer (NSCLC) treated with pemetrexed....
10.
Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426
Adjei A, Mandrekar S, Dy G, Molina J, Adjei A, Gandara D, et al.
J Clin Oncol . 2009 Oct; 28(4):614-9. PMID: 19841321
Purpose: To evaluate the efficacy and toxicity of pemetrexed combined with bevacizumab as second-line therapy for patients with advanced non-small-cell lung cancer (NSCLC) and to correlate allelic variants in pemetrexed-metabolizing...